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Melanoma cells express ganglioside antigens GM3,
GD3, GM2, and GD2 on their surface. This study
examined whether immunization with a melanoma
cell vaccine induced anti-ganglioside antibody
responses in melanoma patients and whether these
responses were correlated with survival. Sixty-six
patients who had received melanoma cell vaccine
immunotherapy after surgical removal of regional
metastatic melanoma were identified. Cryopreserved
serum samples from these patients were used in an
enzyme-linked immunsorbent assay to determine the
IgM antibody levels to GM2, GD2, GM3, and GD3
prior to melanoma cell vaccine treatment and 4 wk
after the first melanoma cell vaccine immunization.
The saccharide portion of glycoproteins and glycolipidscontains immunogenic epitopes that can induce pre-dominantly IgM antibody responses (Hakomori andKannagi, 1983). Gangliosides, which are glycolipidscontaining sialic acids, are normal constituents of
mammalian cell membranes, but their quantity and quality can be
altered during cellular differentiation and malignant transformation.
GM2 and GD2 were the first reported cancer-associated ganglioside
antigens immunogenic in man (Irie et al, 1982). These gangliosides
are expressed in melanoma, neuroblastoma, and brain tumors at a
relatively high density. They differ by only one sialic acid, which
is enough to make them distinct with respect to the human immune
system. Melanoma cells also express GM3 and GD3 as major
gangliosides (Portoukalian et al, 1979; Tsuchida et al, 1987). The
saccharide portions of GM3 and GD3 differ by only one sialic acid.
The difference between GM2 and GM3, and between GD2 and
GD3, is only one sugar, N-acetylgalactosamine. The immuno-
genicity of these four melanoma-associated gangliosides depends
on animal species or strains to be immunized (Kawashima et al,
1992). GM2 and GD2 can induce very strong IgM antibody
responses in man (Tai et al, 1985). GD3, on the other hand, is highly
immunogenic in mice (Ritter et al, 1990). The immunogenicity of
GD3 and GM3 in man has not been clearly demonstrated.
There is clinical and laboratory evidence to suggest that anti-
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All antibody levels significantly increased by week 4
(p < 0.001 for all four antibodies) and all increases
were significantly associated with survival (anti-GD2,
p < 0.001; anti-GM2, p J 0.001; anti-GD3, p < 0.001;
anti-GM3, p < 0.001). Anti-tumor activity of these
antibodies was proved using five representative anti-
body-positive sera in a complement-dependent cyto-
toxicity assay with cultured melanoma cell lines. These
studies suggest that GM2, GD2, GM2, and GD3
expressed by melanoma cells can induce specific IgM
antibodies and that high levels of these antibodies
might have a beneficial impact on survival. Key words:
active specific immunotherapy/ganglioside/IgM antibody/
melanoma. J Invest Dermatol 112:205–209, 1999
ganglioside antibodies have anti-tumor activity. In patients with
melanoma or neuroblastoma, injection of mouse and human anti-
ganglioside antibodies caused tumor regression (Houghton et al,
1985; Irie and Morton, 1986; Irie et al, 1989; Murray et al, 1994;
Handgretinger et al, 1995). Livingston (1995) immunized melanoma
patients with purified ganglioside GM2 and found that the
heightened anti-GM2 antibody level correlated with longer survival.
This study was designed to measure the serum levels of IgM
antibody against GM3, GD3, GM2, and GD2 after initiation of
active immunotherapy with a melanoma cell vaccine (MCV) that
contained these gangliosides (Morton et al, 1992), and to determine
whether these levels were significantly associated with survival.
MATERIALS AND METHODS
Gangliosides GD2 was obtained from Advanced ImmunoChemical
(Long Beach, CA). GM2, GD3, and GM3 were obtained from Sigma (St.
Louis, MO).
Monoclonal antibodies A mouse IgG anti-GD2 monoclonal antibody
(KM666) and a mouse IgG anti-GD3 monoclonal antibody (KM641) were
kindly provided by Kyowa Hakko (Tokyo, Japan). A human IgM anti-GM2
monoclonal antibody (L55–81) and a human IgM anti-GM3 monoclonal
antibody (L612) were prepared in our laboratory (Hoon et al, 1993;
Nishinaka et al, 1996). These antibodies were used as standards in
each enzyme-linked immunosorbent assay (ELISA) plate. Horseradish
peroxidase-conjugated goat anti-mouse IgG (γ-specific) and goat anti-
human IgM (µ-specific) antibodies were obtained from Boehringer (Indian-
apolis, IN).
Tumor cell lines Human melanoma cell lines M12 and M14 were
cultured in RPMI 1640 supplemented with 5% fetal calf serum. M12 cells
express GM3 and GD3 at a high density, and M14 cells express GM2 and
GD2 at a high density (Tsuchida et al, 1987). Therefore these target cell
lines were used for measuring the reactivity of anti-GD3 and anti-GM3
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and of anti-GD2 and anti-GM2, respectively, in immune adherence (IA)
and complement-dependent cytotoxicity assays.
Patients and immunization schedule This study included patients
who had undergone resection of regional metastatic melanoma (American
Joint Committee on Cancer stage III) followed by adjuvant immunotherapy
with MCV. Patients were selected in a retrospective fashion according to
duration of survival following initiation of MCV therapy: .5 y (n 5 22),
2–5 y (n 5 22), or ,1 y (n 5 22). Patients who recurred within 4 mo
after surgery were excluded from the study.
MCV comprises three human melanoma cell lines (M10, M24, and
M101) that express GM3 (36.2%), GM2 (34.7%), GD3 (19.8%), and GD2
(9.3%). MCV is prepared by pooling equal amounts of each cell line to a
total of 2.4 3 107 cells in serum-free medium containing 10% dimethyl
sulfoxide; pooled cells are irradiated to 100 Gy and cryopreserved in liquid
nitrogen until use. Immediately before injection, MCV is thawed and
washed. The vaccine is then injected intradermally in axillary and inguinal
regions on a schedule of every 2 wk 3 3, then monthly for 1 y (Morton
et al, 1992). For the first two treatments, MCV is mixed with Tice strain
of Bacillus Calmette Guerin (BCG) (8 3 106 organisms per vial). After
1 y, the immunization interval is increased to every 3 mo 3 4, then every
6 mo. Follow-up clinical evaluations are repeated monthly.
All patients receiving MCV undergo serum collection at week 0 (pre-
MCV) and at 4, 8, and 16 wk after the first vaccination. In our study, sera
were also collected from 22 healthy donors to serve as a control. All serum
samples were stored at –35°C, thawed, and heated at 56°C for 1 h before
testing. To eliminate bovine-reactive antibodies in sera, absorption was
performed using bovine erythrocytes. Briefly, bovine erythrocytes were
washed six times with RPMI 1640 and adjusted at 2 3 109 cells per ml.
An equal volume of patient serum and the above bovine erythrocyte
suspension was mixed and gently agitated. After incubation overnight at
4°C, supernatant was collected.
IA assay The IA assay is a very sensitive method to detect complement-
binding antibody, especially IgM antibody bound to the surface of tumor
cells, by specific rosette formation of human erythrocytes via complement
activation. IA assay was performed according to the protocol described
elsewhere (Irie et al, 1982). Although IA assay cannot measure each anti-
ganglioside antibody separately, it is a rapid and less expensive assay for
polyclonal anti-ganglioside antibodies and was useful in determining peak
titers of anti-ganglioside antibodies after initiation of vaccine therapy. Sera
from 91 vaccinated patients were tested by IA assay using M14 and M12
cell lines. M14 and M12 cell lines are highly sensitive target cells for the
detection of anti-GM2/GD2 IgM and anti-GM3/GD3 IgM, respectively.
The antibody response to M14 and M12 reached a peak at week 4 after
MCV administration in most patients: 90.1% (82 of 91) with M14 and
82.4% (75 of 91) with M12.
ELISA with ganglioside antigens ELISA was used to measure serum
levels of IgM antibody against purified GM2, GD2, GD3, and GM3.
Three micrograms of each ganglioside in ethanol was added to each well
of 96 well polystyrene microtiter plates (Fisher Scientific, Tustin, CA) and
the plates were dried. The plates were washed twice with phosphate-
buffered saline (PBS) and incubated for 5 h at room temperature with
SuperBlock blocking buffer (PIERCE, Rockford, IL). After one washing
with PBS, sera diluted 1:200 or anti-ganglioside antibodies diluted at an
appropriate working concentration with PBS containing 1% globulin-free
bovine serum albumin (Sigma) (1% BSA-PBS), were added to the wells
and the plates were incubated for 2 h at room temperature. Subsequent
steps followed standard ELISA procedures. Each experiment included two
IgM human monoclonal antibodies (HuMoAb) as positive controls: anti-
GM2 IgM HuMoAb (L55; Nishinaka et al, 1996) and anti-GM3 IgM
HuMoAb (L612; Hoon et al, 1993). The optical density (OD) of background
ranged from 0.011 to 0.092, and the mean OD was 0.031 (SD 5 0.012).
The SD ranged from 0% to 6.1%. All assays were performed in a triple-
blind fashion, i.e., selection of patients, performance of ELISA, and analysis
of data were done independently.
To confirm the IA results for time of peak anti-ganglioside antibody
levels, sera from 43 vaccinated patients were also tested by ELISA using
purified ganglioside antigens. Reactivity to all four gangliosides was highest
at week 4 (76.7%–83.7% of patients). Based on these results, sera obtained
at week 4 were tested by ELISA as post-MCV samples in our study group
of 66 patients.
Sandwich ELISA The total serum IgM concentration was examined
by sandwich ELISA. Ninety-six well microtiter plates were coated with
goat anti-human IgM antibody (MELOY, Springfield, VA). After three
washings with 1% BSA-PBS, the plates were incubated for 5 h with
SuperBlock blocking buffer. Subsequent steps followed the ganglioside
ELISA described above.
Cytotoxic assay To investigate the anti-tumor activity of anti-ganglio-
side antibodies induced by MCV, post-MCV sera were tested by a 4 h
51Cr-releasing complement dependent cytotoxicity assay, using the method
described in a previous report (Nishinaka et al, 1996). L55 HuMoAb (IgM
anti-GM2 antibody) and L612 HuMoAb (IgM anti-GM3 antibody) were
tested as positive controls. M14 and M12 were target cells in vitro. 51Cr
release of the complement alone (background) was subtracted from that of
each serum experiment. Background 51Cr release was no greater than that
of the buffer control.
To determine if cytotoxicity was caused by anti-ganglioside antibodies,
inhibition assay with each ganglioside was performed. Because M14 is a
target cell line for anti-GM2 and GD2 antibodies and M12 is a target cell
line for anti-GM3 and anti-GD3 antibodies, respective gangliosides (10 µg
in serum sample) were used for the inhibition assay.
Statistical analysis The primary hypothesis of this paper is that IgM
antibody levels to GM2, GD2, GM3, and GD3 increase after immunization
with MCV. Secondary hypotheses are that antibody levels differ among
the three groups. To test these hypotheses, the post-immunization antibody
levels for each subject were treated as a multivariate outcome. A generalized
estimating equations (GEE) approach was employed (Liang and Zeger,
1986; Zeger and Liang, 1986). The GEE model explicitly accounts for the
correlation between the four antibody levels within each subject and does
not rely on distributional assumptions of normality. Antibody levels were
modeled as a function of two factors, survival group and antibody type,
while controlling for preimmmunization antibody levels. Interactions
between the levels of the two factors were also included in the model.
The primary and secondary hypotheses were then addressed by taking
certain contrasts between various parameter estimates from the GEE model.
A nominal significance level of 0.05 was employed. To ensure joint
significance of the multiple comparisons, the nominal significance level
was adjusted using the Bonferroni method (Neter et al, 1990).
RESULTS
IgM anti-ganglioside response and survival Figure 1 shows
the results of ganglioside ELISA using pre-MCV (week 0) and
post-MCV (week 4) sera from the three survival groups. Prior to
immunization, there were no intergroup differences in antibody
levels. Immunization with MCV elicited IgM antibody responses to
all four antigens (Table I). All antibody responses were significantly
different between the 5 y and 1 y groups; anti-GD2 antibody
responses were significantly different between the 2–5 y and 1 y
groups; anti-GD3 and anti-GM3 responses were significantly differ-
ent between the 5 y and 2–5 y groups. In each case, the
group with longer survival had the statistically higher level of
serum antibody.
Of interest is whether antibody levels could be used as a
prognostic factor. An OD value separating high and low antibody
responses to MCV was determined for each ganglioside by taking
the upper 95% confidence value for the 1 y survival group. Cut-
off OD values were 0.270 for anti-GD2, 0.393 for anti-GM2,
0.278 for anti-GD3, and 0.490 for anti-GM3. An exact permutation
test for the odds ratio (STATXACT-3.0; Cytel Software, Cam-
bridge, MA) was then computed for the percentage of high
responders in the 5 y and 2–5 y groups relative to the 1 y group.
As shown in Fig 2, anti-GD2, anti-GD3, and anti-GM3 antibodies
clearly distinguished the 5 y group from the 1 y group. A similar
trend was seen with anti-GM2; however, significance was not
attained because of the lower percentage of high anti-GM2
responders in the 5 y group. No anti-ganglioside antibody distingu-
ished between the 2–5 y and the 1 y groups.
Total serum IgM level Mean post-MCV IgM level (OD 6 SD)
was 0.621 6 0.117 in the 5 y group, 0.638 6 0.126 in the 2–5 y
group, and 0.607 6 0.108 in the 1 y group. These levels were not
significantly different: p 5 0.572 for 5 y vs 2–5 y, p 5 0.432 for
5 y vs 1 y, and p 5 0.358 for 2–5 y vs 1 y. The coefficient of
correlation with total IgM was 0.24 for anti-GD2, 0.38 for anti-
GM2, 0.29 for anti-GD3, and 0.31 for anti-GM3. Thus the
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Figure 1. IgM anti-ganglioside antibodies by ELISA in sera of melanoma patients at weeks 0 and 4. All sera were tested at 1:200 dilution.
The statistical differences in these results are tabulated in Table I.
Table I. Statistical significance (p value by parameter contrasts from a GEE model) of overall and intergroup differences
in anti-ganglioside IgM antibody levels 4 wk after first immunization with MCV
Intergroup comparisons in post-MCV means (p value)
Pre- versus post-MCVa
IgM antibody mean (p value) 5 vs 2–5 y 5 vs 1 y 2–5 vs 1 y
GD2 0.249 (,0.001)b 0.071 (0.089) 0.151 (,0.001)c 0.080 (0.001)c
GM2 0.309 (,0.001)b 0.090 (0.017) 0.135 (,0.001)c 0.044 (0.080)
GD3 0.275 (,0.001)b 0.160 (0.001)c 0.211 (,0.001)c 0.051 (0.020)
GM3 0.386 (,0.001)b 0.133 (,0.001)c 0.209 (,0.001)c 0.076 (0.025)
aPre-MCV 5 week 0; Post-MCV 5 week 4.
bBonferroni adjusted for four comparisons. Significant at p , 0.01.
cBonferroni adjusted for 12 comparisons. Significant at p , 0.004.
augmentation of anti-ganglioside antibodies by MCV was independ-
ent of general IgM production in these patients.
Complement dependent cytotoxicity of serum anti-ganglio-
side antibodies induced by MCV Random selection was used
to identify five patients with elevated post-MCV serum titers of
IgM against at least one of the four gangliosides. Complement
dependent cytotoxicity assay using these sera showed cytotoxic
activity against M14 target cells (patients A–D) and M12 target
cells (patients B and E) (Table II). None of the pre-MCV sera
from the same patients showed cytotoxic activity against M14 and/
or M12 (data not shown). To determine if this cytotoxicity was
caused by anti-ganglioside antibodies, an inhibition assay was
performed using GM2 and GD2 to block binding to M14 target
cells, and GM3 and GD3 to block binding to M12 target cells.
This assay showed partial or complete inhibition of cytotoxic
activity in serum from all five patients (Table II). Thus, MCV
immunization induced anti-ganglioside antibodies that had the
ability to kill antigen-positive melanoma cells.
DISCUSSION
Although all 66 patients received MCV on the same treatment
schedule (Morton et al, 1992), the pattern of antibody responses
was quite diverse. The strongest IgM antibody response was to
GM2, followed by GM3 (Fig 1). Interestingly, many patients had
anti-GM3 antibody at week 0, presumably the result of GM3
expressed on the surface of dysplastic nevi, primary melanoma, and
metastatic melanoma (Carubia et al, 1984; Saito et al, 1990). Post-
MCV (week 4) anti-GD2 antibody levels were low, possibly
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Figure 2. Percentage of patients whose sera displayed an OD value
higher than the cut-off OD value. The cut-off OD value was determined
by taking the upper 95% confidence value for the 1 y survival group. The
cut-off values were 0.270 for anti-GD2, 0.393 for anti-GM2, 0.278 for
anti-GM3, and 0.490 for anti-GD3. u, 5 y group; g, 2–5 y group; j,
1 y group. The p value from a test of the odds ratio compares the
percentage of high responders in 5 y and 2–5 y groups with that in the 1
y group.
Table II. Cytotoxic activity of anti-ganglioside antibody
induced by MCV (week 4)
Target Inhibited Cytotoxicityb % Inhibition
cells bya (%)
Patient A M14 – 43.3 6 3.1
GM2 12.0 6 1.5 72.3
GD2 36.1 6 2.9 16.6
Patient B M14 – 15.9 6 3.4
GM2 13.6 6 1.1 14.5
GD2 4.4 6 1.7 72.3
Patient C M14 – 39.0 6 5.7
GM2 35.2 6 4.7 9.7
GD2 ,0.1 100
Patient D M14 – 11.4 6 1.5
GM2 5.3 6 1.5 53.5
GD2 ,0.1 100
Patient B M12 – 29.7 6 3.2
GM3 25.7 6 2.9 13.5
GD3 ,0.1 100
Patient E M12 – 11.5 6 0.5
GM3 7.2 6 1.8 37.4
GD3 3.5 6 4.1 69.6
L55 HuMoAbc M14 – 72 1 1.2
GM2 ,0.1 100
L612 HuMoAbc M12 – 63 1 3.1
GM3 ,0.1 100
aTen micrograms per ml of each ganglioside was incubated with serum samples
overnight at 4°C.
b51Cr-releasing assay was used to test cytotoxic activity. All tests were done
in triplicate.
cOne hundred micrograms per ml of HuMoAb was used.
reflecting the relatively low percentage (9.3%) of GD2 in MCV.
Although GD3 is expressed on MCV cells in greater density than
GM2 or GD2 and comparable density to GM3, anti-GD3 antibody
levels showed the smallest change before and after MCV. We thus
conclude that of the four gangliosides, GD3 is the weakest
immunogen and GM2 may be the strongest. Reports by Livingston’s
group (Ritter et al, 1991; Livingston et al, 1995) support this
conclusion. They used purified GD3 and GM2 to immunize
melanoma patients. Patients responded strongly to GM2 but did
not respond to GD3.
Immunogenicity of gangliosides may be regulated by host genetic
factors such as HLA or blood type. Despite repeated immunizations
with MCV, some patients never developed detectable anti-ganglio-
side antibody responses. Also, certain patients had extremely high
antibody levels to GD3, which is a weaker immunogen. A
differential response to various gangliosides may also reflect acquired
immunologic tolerance or induced immunologic suppression against
certain ganglioside antigens. Alternatively, immune recognition of
gangliosides may be interrupted by the surrounding membrane
component of melanoma, which competitively inhibits the ganglio-
side epitopes. This possibility is supported by the low rate of
antibody-detected gangliosides on the surface of normal melanocytes
versus melanoma cells (Hakomori, 1989), and the comparable
content of GM3 between the two cell types when this ganglioside
is extracted biochemically. Finally, differences in the configuration
or conformation of the saccharide moiety may affect the response
to various gangliosides.
Serum antibodies against DNA, cytoplasm, nucleus, and platelets
have been used for clinical diagnosis of autoimmune diseases, but
thus far there are no FDA-approved anti-tumor antibodies for
diagnosis or prognosis of cancer patients. This is partly because
neoplastic cells are heterogeneous between individual patients and
even within the same patient. Additionally, anti-tumor autoantibody
levels are usually too low for detection by in vitro tests. In our
study, pre-MCV antibody levels were very low in most patients,
and we could not examine their intergroup differences; however,
high post-MCV levels of anti-GD2 and anti-GD3 IgM antibodies
were significantly associated with longer survival (5 y group). These
findings indicate that at the present time, measurement of serum
anti-ganglioside antibody levels is of clinical significance only in
patients whose antibody levels are augmented by active specific
immunotherapy.
Although this study did not show direct evidence of an in vivo
anti-tumor effect by anti-ganglioside antibodies, there is sufficient
circumstantial evidence to suggest that augmentation of IgM anti-
ganglioside antibodies by MCV may be of benefit to melanoma
patients. First, only a small fraction of patients showed an appreciable
amount of anti-ganglioside antibodies before vaccination, but the
ganglioside-rich MCV augmented anti-ganglioside antibodies in
a significant number of patients. Second, IgM anti-ganglioside
antibodies induced by MCV were able to kill melanoma cells in
the presence of complement in vitro (Table II). Livingston et al
(1995) demonstrated that anti-GM2 antibody augmented with pure
GM2 antigen correlated with a good prognosis of melanoma
patients. In our study, antibodies to all four melanoma-associated
ganglioside antigens were significantly higher in the 5 y group than
the 1 y or 2–5 y group. Lastly, the high serum levels of the anti-
ganglioside antibodies did not cause any autoimmune diseases or
toxicity in these patients. Development of a more potent vaccine
that can induce IgM anti-ganglioside antibodies in a majority of
patients may further improve the management of melanoma.
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